Aceto Corporation (NASDAQ:ACET) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday.

According to Zacks, “Aceto Corporation markets, sells and distributes finished dosage form generics, nutraceutical products, pharmaceutical intermediates and active ingredients, agricultural protection products and specialty chemicals. The company’s operating segment consists of Human Health, Pharmaceutical Ingredients and Performance Chemicals. Human Health segment supplies raw materials used in the production of nutritional and packaged dietary supplements. It markets and distributes its generic prescription and over the counter pharmaceutical products. Pharmaceutical Ingredients segment offers active pharmaceutical ingredients and pharmaceutical intermediates. Performance Chemicals segment provides specialty chemicals. It serves chemical, agricultural, human health and pharmaceutical industries. The company operates primarily in United States, Europe, and Asia. Aceto Corporation and is headquartered in Port Washington, New York. “

Separately, ValuEngine cut Aceto Corporation from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Four equities research analysts have rated the stock with a hold rating, The stock presently has a consensus rating of “Hold” and a consensus price target of $22.50.

Aceto Corporation (ACET) traded down 0.13% during mid-day trading on Tuesday, hitting $15.20. The company had a trading volume of 108,236 shares. Aceto Corporation has a 52-week low of $13.50 and a 52-week high of $25.98. The company has a 50-day moving average price of $14.71 and a 200 day moving average price of $16.54. The company has a market capitalization of $457.52 million, a P/E ratio of 29.01 and a beta of 1.26.

Aceto Corporation (NASDAQ:ACET) last announced its earnings results on Thursday, May 4th. The company reported $0.39 EPS for the quarter, missing analysts’ consensus estimates of $0.44 by $0.05. Aceto Corporation had a net margin of 2.79% and a return on equity of 11.15%. The firm had revenue of $190.10 million for the quarter, compared to analysts’ expectations of $195.09 million. During the same quarter last year, the business earned $0.42 earnings per share. The business’s revenue was up 20.4% compared to the same quarter last year. On average, analysts forecast that Aceto Corporation will post $1.36 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Friday, June 23rd. Investors of record on Friday, June 9th were issued a dividend of $0.065 per share. This represents a $0.26 dividend on an annualized basis and a yield of 1.71%. The ex-dividend date was Wednesday, June 7th. Aceto Corporation’s dividend payout ratio (DPR) is 50.00%.

TRADEMARK VIOLATION NOTICE: This news story was published by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/07/11/zacks-investment-research-upgrades-aceto-corporation-nasdaqacet-to-hold.html.

In other Aceto Corporation news, Chairman Albert L. Eilender sold 6,500 shares of the stock in a transaction dated Thursday, July 6th. The stock was sold at an average price of $15.21, for a total value of $98,865.00. Following the sale, the chairman now owns 252,029 shares of the company’s stock, valued at approximately $3,833,361.09. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Charles John Alaimo sold 2,612 shares of the stock in a transaction dated Wednesday, July 5th. The shares were sold at an average price of $15.48, for a total value of $40,433.76. Following the completion of the sale, the insider now directly owns 15,017 shares in the company, valued at approximately $232,463.16. The disclosure for this sale can be found here. Insiders have sold a total of 25,982 shares of company stock valued at $397,906 over the last 90 days. 4.10% of the stock is currently owned by company insiders.

A number of large investors have recently bought and sold shares of ACET. Dimensional Fund Advisors LP raised its stake in Aceto Corporation by 10.0% in the first quarter. Dimensional Fund Advisors LP now owns 2,396,238 shares of the company’s stock worth $37,885,000 after buying an additional 218,781 shares in the last quarter. Champlain Investment Partners LLC raised its stake in Aceto Corporation by 15.1% in the first quarter. Champlain Investment Partners LLC now owns 1,432,580 shares of the company’s stock worth $22,649,000 after buying an additional 187,980 shares in the last quarter. Deprince Race & Zollo Inc. raised its stake in Aceto Corporation by 131.8% in the first quarter. Deprince Race & Zollo Inc. now owns 1,254,547 shares of the company’s stock worth $19,834,000 after buying an additional 713,284 shares in the last quarter. State Street Corp raised its stake in Aceto Corporation by 3.4% in the fourth quarter. State Street Corp now owns 697,707 shares of the company’s stock worth $15,330,000 after buying an additional 23,185 shares in the last quarter. Finally, Hillcrest Asset Management LLC raised its stake in Aceto Corporation by 35.1% in the first quarter. Hillcrest Asset Management LLC now owns 551,357 shares of the company’s stock worth $8,717,000 after buying an additional 143,355 shares in the last quarter. 81.13% of the stock is currently owned by institutional investors.

About Aceto Corporation

Aceto Corporation (Aceto) is engaged in the marketing, sales and distribution of finished dosage form generic pharmaceuticals, nutraceutical products, pharmaceutical active ingredients and intermediates, specialty performance chemicals inclusive of agricultural intermediates and agricultural protection products.

Get a free copy of the Zacks research report on Aceto Corporation (ACET)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aceto Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aceto Corporation and related companies with MarketBeat.com's FREE daily email newsletter.